High rates of elevated diabetes distress in research populations: A systematic review and meta-analysis by Dennick, K et al.
 1 
 
Abstract 
Background 
Diabetes distress is a unique phenomenon with empirically established implications for 
diabetes end-points. Interventions targeting diabetes distress are indicated and emerging 
evidence suggests effectiveness, yet preliminary work quantifying and characterising the 
problem is required. 
Objectives 
To identify the presence, potential magnitude (i.e. rate) and determinants of elevated diabetes 
distress across study populations and isolate candidate populations with the greatest need.  
Methods 
Medline, Psychinfo and Embase were searched for studies (n ≥50) assessing diabetes distress 
using the Problem Areas in Diabetes scale or Diabetes Distress Scale, in adult populations 
with diagnosed Type 1 or 2 diabetes. Random effects meta-analysis and meta-regression 
estimated the average rate of elevated diabetes distress and prognostic contribution of age, 
gender, HbA1c and health care context. 
Results 
Of 16,627 citations identified, adequate data were available for 58 studies. On average 22% 
(95% CIs 19% to 26%, P<0.0001) of participants reported elevated diabetes distress. Only 
female gender (β=-2.6, 95% CIs -4.17 to -0.97, P=0.002) and secondary care (β=-0.66, 95% 
CIs -1.18 to -0.14, P=0.01) were independently prognostic of a higher rate of elevated 
distress, albeit younger age (β=-0.03, 95% CIs -0.05 to -0.01, P=0.003) was significant in 
univariate analyses. 
Conclusions 
On average a quarter of people with diabetes have a level of diabetes distress likely to impact 
outcomes. Secondary care practitioners should be particularly vigilant of younger women 
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with diabetes. These findings are limited by unexplained heterogeneity between studies, 
reliance on unrepresentative study samples and issues associated with measuring diabetes 
distress. 
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Introduction 
Diabetes Distress (DD) is characterized by a range of different negative emotional reactions, 
for example worry, fear, anger and feeling overwhelmed etc., to adverse aspects of living with 
and managing diabetes [1].  DD is independently associated with HbA1c [2-7]. Fluctuations 
in each are related over time reflecting the ongoing negative experience of DD and its 
implications for outcomes and vice versa [4, 5]. Adults who experience intervention related 
improvements in DD also evidence clinically relevant improvements in HbA1c [8-10], and a 
10 point change in Problem Areas in Diabetes (PAID) scale scores is associated with a change 
of .2% in HbA1c [6, 9]. DD also impacts certain self-management behaviors (SMBs) [2, 3, 5, 
11, 12].  
 
Individuals with elevated, or ‘clinically relevant’, DD additionally participate less in 
educational and self-management interventions comprising no psychological component [8] 
and exhibit less improvement in HbA1c [10]. Conversely where interventions target DD those 
with elevated DD, but not depression, engage to a greater degree and evidence improvement 
in SMBs [13]. Ameliorating DD is therefore a priority and interventions must move towards 
targeting elevated DD to improve well-being, SMBs and clinical end-points [13, 14]. Such 
endeavours must begin at the ground level with systematic consideration of the presence, 
magnitude and determinants of elevated DD, serving to identify the potential size of the 
problem and isolate candidate populations with the greatest need for intervention.  
 
There is emerging evidence of the rate of elevated DD in study samples. In UK primary care, 
21% of adults report elevated DD [15]. In the Netherlands, 4% and 19% of primary and 
secondary care patients, respectively, experience elevated DD [16]. In Australia, elevated DD 
affects 28%, 22% and 17% of adults with Type I and Type 2 diabetes, using and not using 
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insulin, respectively [17]. The USA community point prevalence of elevated DD is 18%, 
which increases to 48% over an 18 months period [18]. The prevalence and determinants of 
depression in diabetes has been reviewed extensively [19, 20]. Equivalent evidence on DD 
has thus far not received the same attention. A question therefore remains; what is the average 
rate of elevated DD in research populations and what individual and contextual characteristics 
determine this rate? 
 
Objectives 
To identify the average rate and determinants of elevated DD across study populations of 
adults with diabetes.  
 
Method 
A systematic review was undertaken according to the MOOSE (Meta-analysis Of 
Observational Studies in Epidemiology) Group guidance [21]. 
 
Identification of studies 
Medline, Psychinfo and Embase were searched without language restrictions (1995 to 2013). 
In an initial scoping search we found all of the relevant evidence in psychology or medically 
led, rather than nursing led, studies hence it made sense to search these databases. The 
objective of the review was to bring DD to the attention of diabetes nurses and influence 
nursing practice around identifying and managing DD which we believe to be core diabetes 
nursing practice.  
 
Included were studies assessing DD using the PAID scale  [22] or Diabetes Distress Scale 
(DDS) [23] in any adult (≥18 years of age) population with diagnosed Type 1 or 2 diabetes. 
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Studies using anything other than the full versions of the widely adopted PAID or DDS were 
excluded to encourage homogeneity in outcome assessment.. We included a heterogeneous 
range of study populations as the objective of the review was to derive a preliminary 
indication of the average size of the problem and explore this clinical and methodological 
heterogeneity as potential sources of anticipated variation in rates of elevated DD. A broad, 
two pronged search strategy (available from the authors) captured terms historically used to 
describe the experience of DD, and the above measures, and terms that identify the types of 
studies known to include measures of DD as indicated by the initial scoping search; a) 
‘diabetes distress’  text words (all known variants and terms describing measures of DD), and 
b) index terms and text words relating to ‘diabetes’ AND, for example, ‘distress’, ‘mood, 
‘emotion’, ‘depression’, ‘quality of life’, ‘education intervention’, ‘self-management 
intervention’ and ‘psychological intervention’. The strategy was also informed by search 
strategies employed in systematic reviews of depression in diabetes as DD often features in 
such studies.  
 
Selection of studies 
Two reviewers independently assessed citations and full papers for eligibility. Inter-rater 
reliability was good (kappa=.88). Identified conference abstracts and study protocols were 
included and the full papers were requested from authors once initially and then again prior to 
drafting the final paper.  
 
Data extraction 
Data were extracted by one investigator and quality checked by a second, with discrepancies 
resolved by discussion and consensus. No investigator extracted data from their own study. 
Data were extracted on population and setting, sample size, study design, measure of DD, and 
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the rate of elevated DD. Where studies were reported in more than one publication data were 
extracted from the paper reporting the rate of elevated DD. Where necessary demographic 
data were extracted from another publication on the same study (where n was equivalent). 
Baseline data were included for prospective studies. Rate data were requested from authors 
once where this was not reported in the paper(s).  
 
Quality assessment 
A number of tools are available for assessing the risk of bias in randomised controlled trials 
(RCTs), but assessment of observational study designs is controversial. Unlike aspects of 
RCT design, such as randomisation and allocation concealment, there is little evidence that 
criteria against which observational studies are appraised are related to risk of bias [21]. 
Consistent with the conclusion of authors of similar reviews, quality assessment was therefore 
not meaningful and not undertaken [19]. The synthesis was, however, informed by a more 
robust estimate of quality; studies were inverse-variance weighted to ensure that larger, and 
more precise, estimates were given more weight. 
 
Publication bias 
Risk of publication bias was determined by visual inspection of funnel symmetry in the plot 
of each studies estimate against its standard error (SE) and statistical test (Egger’s test). 
 
Specification of outcome 
‘Rate data’ constituted the number, and proportion, of participants completing the PAID scale 
or DDS that scored ≥40 or ≥3 respectively. In the absence of a gold standard criterion for 
identifying clinically relevant DD other means of establishing this have been proposed. A 
PAID score ≥40 is one standard deviation (SD) above the mean for clinic patients and 
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research populations [24, 25] and has discriminant validity [25].  A DDS score ≥3 exhibits 
maximal associations with diabetes outcomes (i.e. SMBs and HbA1c) [11]. These thresholds 
are typically employed in clinical and research settings [26, 27].  
 
Data synthesis  
Meta-analysis was used to estimate the average proportion of elevated DD (and 95% 
confidence intervals, CIs) across studies and pre-defined sources of heterogeneity in the 
estimate were explored using meta-regression. These analyses were undertaken using Metafor 
(R). Inspection of the data suggested normal distributions thus parametric analyses were 
appropriate. Rate data were combined, and covariates explored, in random/mixed effects 
models as statistical heterogeneity beyond that which can be explained by sampling 
error/chance (and the included covariates) is anticipated amongst observational studies [21]. 
This accounts for such heterogeneity and derives more conservative estimates of precision 
and significance. Data were pooled irrespective of diabetes type because preliminary analysis, 
including only exclusively Type 1 or Type 2 samples, suggested this was not prognostic (β=-
0.27, 95% CIs-0.80 to 0.25, P=0.31). 
 
Exploration of heterogeneity 
Statistical heterogeneity was quantified by visual inspection of forest plots and statistical test 
(Q, τ² and I²). τ² provides an estimate of the total variance between studies (i.e. it’s square root 
reflects the standard deviation of the individual study estimates about the average). I² 
represents the percentage of this variance that is above that which would be expected as a 
result of sampling error; 25%, 50% and 75% indicate low, medium and high levels of 
heterogeneity respectively [28]. 
 
 8 
 
Covariates 
Covariates were age, gender (% male), HbA1c and health care context (i.e. 
community/primary care versus secondary care). Covariates were limited to study-level 
variables consistently reported across studies and with a substantive evidence base suggesting 
an association with DD. Multicollinearity was assessed with Pearson’s correlations, 
independent t tests and chi square tests (in SPSS). Covariates were explored in separate 
models then forced simultaneously into a multivariate model to explore the independent 
influence of each.  
 
Sensitivity analyses 
Rate data were pooled irrespective of outcome measure because the PAID and DDS were 
largely developed by the same investigators and there are few discernible differences in their 
theoretical underpinnings, development work, and broad item content. Nonetheless the meta-
analysis was repeated excluding studies that utilized the DDS to observe the resiliency of the 
pooled estimate to the outcome measure employed. The multivariate meta-regression was also 
repeated with multiple imputation of missing values to observe the resiliency of the 
conclusions to listwise deletion of studies with missing data on one or more variables (n=14 
studies; 24%). The imputation process consisted of four stages: extraction of the incomplete 
data-set; imputation of the missing data set; analysis of the results from each data-set; and 
pooling of these results. An assumption was made that data were missing at random. 
Imputation was undertaken using MICE (R), with 24 iterations [29] using predictive mean 
matching for numerical variables and logistic regression for 2-level factors [30, 31]. The 
resulting pooled data-set was passed to Metafor for subsequent analysis [32]. The complete 
code for this is available upon request. Pooled QE and QM chi-square statistics were 
estimated in SAS [33]. 
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Results 
Identification and selection of studies 
The search identified 16,627 unique citations and 149 unique studies, that used the full PAID 
or DDS and with a sample ≥50, were included. Figure 1 illustrates the study flow. Rate data 
were available in 15 papers and were requested from 101 authors 41 (41%) of whom provided 
this. In some instances anonymised patient-level data were provided with an unexplained 
discrepancy between the number of participants reported in the paper and those included in 
the dataset. Authors were contacted once to resolve this. Failing this studies were included if 
the discrepancy was ≤10% (and demographic data were estimated from the dataset provided 
where possible). Three studies were excluded owing to a >10% unresolved discrepancy. Rate 
data were available for another four studies acquired during contact with authors, or whilst 
cross-checking included studies with PAID and DDS authors, or identified since the search 
was completed. The final number of included studies was 58 (one study reported on two 
distinct samples; s44 and s45), representing 17,667 participants. DD data were available for 
16,659 of these participants. Table 1 comprises the reference list of included studies. 
 
Figure 1 Flowchart of included studies 
 
Table 1 Reference list of included studies 
 
Publication bias 
Funnel plot symmetry and a non-significant Egger’s test suggested publication bias was 
unlikely (P=0.41). 
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Characteristics of included studies 
The characteristics of the included studies are summarised in Table 2. Studies were 
undertaken in 14 different countries, predominantly the USA (n=14), the UK (n=11) and the 
Netherlands (n=11), and samples were largely derived in community settings (n=15) and 
hospital diabetes clinics (n=35). Thirty were intervention studies, two thirds of which were 
RCTs, whilst the remaining studies were observational (and all data were baseline except for 
one RCT; s19). Average participant characteristics were male 49% and mean age was 54.5 
yrs. Where ethnicity was reported samples were predominantly Caucasian (n=11) or African 
American/Black (n=6). Type 2 and Type 1 diabetes were the sole populations in 33 and 11 
studies respectively, whilst the remainder of the samples were mixed. Of the mixed and Type 
2 samples reporting this, on average 76% and 35% of participants were treated with insulin or 
other injectables respectively. Most studies used the PAID (n=51). One of these studies 
employed both the PAID and DDS (s27). To ensure that this study was not too heavily 
weighted in the meta-analysis only the PAID data were included to promote homogeneity in 
outcome. Hba1c (n=9), depression (n=7), DD (n=3), and physical co-morbidity (n=1) 
inclusion criteria were employed in 18 studies (one study employed both HbA1c and DD and 
another both DD and depression). Mean HbA1c was 7.8% (61.7mmol/mol) and was ≥7.5% 
(58.5 mmol/mol) in 36 studies (n=51). Levels of DD as measured via the PAID and DDS 
were 28.3 (n=43; range 10.2-51.0) and 2.3 (n=5; range 1.9-2.5) respectively.  
 
Table 2 Characteristics of included studies 
 
Meta-analysis 
The average proportion of elevated DD was 0.22 (95% CIs 0.19 to 0.26, p<.001). This was 
associated with a significant amount of heterogeneity (Q(df=57) = 1456.7, p<0.001; τ²=0.51), 
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almost all of which reflected real differences between the studies rather than sampling error 
(I²=96.1%). The forest plot is illustrated in Figure 2. 
 
Figure 2 Forest plot illustrating the rate of elevated diabetes distress across all study 
populations 
 
Meta-regression 
Age was associated with all of the other variables; gender (r=.3, P=0.03), HbA1c (r=-0.5, 
P<0.001) and health care context (t(46.18)=-3.7, P=0.001) whilst none of the other variables 
were related (P>0.05). The results from the meta-regression analyses are presented in Table 3. 
In the univariate analyses gender, age and health care context were significantly prognostic 
(P<0.05), whilst HbA1c was not (P>0.05). The multivariate model was significant (QM(df=4) 
= 21.6, p=<0.001) but only 10% of the heterogeneity in study estimates was accounted for. 
Only gender and health care context emerged as significantly prognostic (P<0.05). Significant 
heterogeneity remained (QE(df=39) = 924.5, P<0.001; τ²=.49), almost all of which reflected 
real differences between the studies (I²=95.8%).  
 
Table 3 Participant characteristics as predictors of the rate of elevated diabetes distress 
 
Sensitivity analysis 
The observed estimate was not apparently influenced by variation in the measures of DD 
employed; the proportion of elevated DD based on samples utilizing the PAID was 0.23 (95% 
CIs 0.19 to 0.26, P<0.001) and this was still associated with substantial heterogeneity 
(Q(df=50) = 1207.8, P<0.001, τ²=0.51; I²=95.9%). Imputation of missing data largely 
generated the same conclusions (QM(df=4) = 4.64, p=<0.001; QE(df=53) = 24.3, P<0.001); 
gender (β=-1.34, 95% CIs -2.49 to -0.20, P=0.02) remained within conventional significance 
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levels in the multivariate meta-regression but health care context was reduced to marginal 
significance (β=-0.35, 95% CIs -0.73 to 0.02, P=0.07). Age (β=-0.01, 95% CIs -0.03 to 0.01, 
P=0.31) and HbA1c (β=0.04, 95% CIs -0.24 to 0.31, P=0.79) were again not significantly 
prognostic. 
 
Conclusions 
Summary of findings 
We identified a substantial number of studies that included a measure of DD suggesting it to 
be a universally relevant phenomenon. On average one in every four people with diabetes has 
a level of DD likely to impact clinical outcomes. This estimate was apparently relatively 
precise. The estimated prevalence of diabetes amongst adults in England in 2015 was 
2,913,538 [34]; translating to almost 650,000 people with diabetes who may be experiencing 
elevated DD at any one time. In the univariate analysis there were multiple significant 
predictors of elevated DD; younger age, female gender and secondary rather than primary 
care, but in a multivariate model only gender emerged as significant in both the complete case 
and multiple imputation analyses suggesting that gender may be the strongest and most 
consistent determinant.  A 1% increase in the proportion of females in study samples was 
associated with at least a 1.3% higher rate of elevated DD. health care context was reduced to 
marginal significance in the imputation analysis yet this is still a potentially important effect; 
p values reflect the strength of evidence against the null hypothesis and those falling slightly 
outside the arbitrary convention of P<0.05 may still be of importance [35]. The rate of 
elevated DD does not appear to be sensitive to diabetes type or the measure of DD employed.  
 
The observed estimate was associated with significant heterogeneity, though, with rates 
ranging from 3-54% and only 10% of this variance was explained by the covariates tested. 
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There are likely other unexplored variables that would explain the rates of elevated DD 
observed. The average estimate should therefore be interpreted with caution and considered 
an initial indication of the potential rate of elevated DD in any particular population.  
 
Our findings in relation to wider evidence  
The potential rate of elevated DD observed is equivalent to depression in diabetes [20, 36]. 
Elevated DD has been reported to be more prevalent in secondary than primary care [16] and 
levels of DD are consistently higher for women [12, 37-41]. The latter is also consistent with 
systematic reviews of depression and anxiety in diabetes [20, 42]. This association may be 
explained by increased mood reporting, albeit this has been contested [43], or other 
unmeasured third variables; elevated rates of DD in women are at least partially underpinned 
by a known greater propensity for diabetes morbidity in women [44, 45]. Younger age [12, 
46, 47] has previously demonstrated an independent association with DD but this was not 
confirmed. Whilst gender, and to a far lesser extent health care context, emerged as the 
‘strongest' predictors of elevated DD, however, health care practitioners should consider that 
younger age was prognostic in the univariate analyses. Clinically it is dangerous to conclude 
that these variables explain everything and ignore other such determinants. This is especially 
important given that multicollinearity between age and the other predictor variables and that 
this resulted in limited the statistical power for detecting individual effects. The previously 
demonstrated association between DD and HbA1c [4, 5, 39] was additionally not confirmed. 
This relationship is modest [23, 48], somewhat variable [49, 50], and influenced by study 
characteristics such as the measure of DD used; DD exhibits a stronger association with 
HbA1c when measured via the DDS rather than the PAID (which the majority of the included 
studies employed) [51]. Equivalent rates of elevated DD by diabetes type, when measured via 
the PAID, have similarly been observed in primary studies [51]. 
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Strengths and limitations  
Despite the now vast DD evidence base this is the first systematic attempt to identify the 
presence, potential magnitude, and determinants of elevated DD and isolate candidate 
populations with the greatest need for intervention. We employed a comprehensive search to 
ensure capture of papers not indexed in terms of DD, endeavoured to eliminate bias at each 
stage of the review process, and made a concerted effort to obtain outcome data. Owing to the 
large number of studies with highly variable results we do not anticipate that additional 
studies would alter the conclusions. We recently updated our search and reviewed studies 
undertaken in samples with Type 1 diabetes and again observed that 20–30% of participants 
experience elevated DD [52]. Recent studies in mixed and Type 2 samples also fall within the 
observed range [51, 53, 54].  
 
This review is not withstanding limitations, though. Firstly the observed estimate may be 
influenced by sampling bias. Only three databases were searched [21], rate data could not be 
obtained for over half of the studies identified, studies rarely employed sampling strategies to 
derive a representative sample, and demographic and DD data were occasionally reported for 
participants completing the study or included in analysis; in 31 (57%) studies the number of 
participants for whom rate data were available was less than those included in the study and 
for whom demographic data were reported (mean difference in n was 37 (SD 47.6), range 1-
155). People with elevated DD are hard to reach, and perhaps less likely to participate in 
research and more likely to ‘drop out’ when they do. There was additionally a bias to the 
western world and non-ethnic minorities, and non-English language papers were not 
translated. The findings cannot therefore be extended to other cultures and ethnic minorities. 
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Secondly, there are issues associated with the measurement of DD. The thresholds taken to 
indicate elevated DD are not diagnostic. Whilst the sensitivity analysis suggested equivalence 
in the rate of DD indicated by the PAID and DDS thresholds employed, these thresholds were 
derived via different assumptions and whether they actually equate to ‘clinically meaningful’ 
DD is to some extent unknown, especially for the PAID. There is also a lack of 
standardisation in the scoring of the PAID.  This is scored on a 5-point Likert scale from 1-5 
or 0-4 yielding scores that range from 0-80 or 20-100 respectively, and it is recommended that 
the 0-80 scores are standardised to a 0-100 scale. These distinct scoring systems result in 
different estimates of the rate of elevated DD. Evidence of variation in approach was observed 
but the impact could not be explored owing to poor reporting of the scoring system used. In 
addition, DD arises from multiple sources and a moderate total score may result should a 
respondent endorse one aspect of DD but not another hence underestimating the clinical 
impact of DD for this person. Exploration of the distinct sources of DD would likely result in 
higher rates of elevated DD.  
 
Implications for clinical practice 
Health care practitioners should work on the assumption that a quarter of their patients may 
be experiencing a level of DD that requires attention. For some people DD is transient arising 
at certain points in the diabetes illness trajectory and subsiding again [55]. Screening for 
elevated DD as part of routine practice is indicated, especially when milestones such as 
progressing to insulin treatment and issues relating to glycemic control, acute 
episodes/inpatient admissions, and the development of complications, are encountered. 
Importantly secondary care practitioners should be particularly vigilant of younger, female 
patients. Validated screening tools exist for this purpose. Clinicians should explore the 
source(s) of even moderate DD. The DDS sub-scales lend themselves particularly well to this 
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task. Screening is only appropriate, though, when clear care pathways for DD exist [56] and at 
present this is infrequently the case. The research evidence, and detection and management of 
DD in clinical practice, is in its infancy; few intervention studies have specifically targeted 
DD [57]. The emerging evidence base is encouraging though; we previously identified 
interventions, and intervention components, that may be associated with improvement in DD 
[52, 57]. 
 
Recommendations for further research 
Epidemiological studies establishing the population level prevalence, and predictors, of 
elevated DD are required. Such endeavours should extend beyond the western world to other 
cultures and ethnic minorities known to be particularly afflicted with diabetes, for instance 
South East Asians, and should adopt consistency in the use of thresholds and scoring systems 
for the PAID. Given the transient nature of DD estimates of ‘point prevalence’ underestimate 
the magnitude of the problem [18], and prospective studies are required to further explore the 
‘lifetime prevalence’ of DD. Finally intervention development endeavours specifically 
targeting elevated DD for female, and perhaps younger patients, with more complex diabetes 
should now be considered. 
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Figure 1 Flowchart of included studies 
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T1/2 Y Y  N N 23.1 
(18.8)  
7.9 
(1.4) 
(62.8)  
54.2 
(14.8)  
814/1567 
(52%)  
NR NR 297/1567 
(18.9%) 
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Byrne 2012a  
UK 
437 Diabetes 
clinic 
(I/RCT) 
T1 N N Y N 29.9 
(19.0)  
NR 40.8 
(11.7) 
202/437 
(46%) 
NR All 129/423 
(30.5%) 
s8 
Chawla 2010a 
USA  
62 
(demographics 
for 61 
included in 
analysis) 
Primary care 
(I/non-RCT) 
T1/2 N N N N 16.0 
(13.2)  
7.7 
(1.5) 
(60.7)  
60.8 
(NR) 
30/61 
(49%) 
All 
Caucasian  
NR 4/61 
(6.6%)  
s9 
Due-Christensen 
2012  
DENMARK 
 
54 Diabetes 
clinic (I/non-
RCT) 
T1 N N N N 37.4 
(16.1
6) 
8.2 
(1.3) 
(66.1) 
43.8 
(10.5) 
11/54 
(20%) 
NR All 29/54 
(53.7%)  
s10 
Engel 2011b 
AUSTRALIA 
 
648  
(MDI&CSII 
groups at 
baseline – 
demographics 
for n 
providing data 
on that 
variable) 
Diabetes 
clinic (I/non-
RCT)  
T1 N N N N 29.6 
(21.2)  
7.6 
(1.2) 
(59.6) 
48.8 
(14.7) 
265/636 
(42%) 
NR 
(Australian 
(81.5%) 
All 172/594 
(28.9%)  
s11 
Fisher 2011  
USA 
 
483 Primary care 
(I/RCT) 
T2 N N Y N 2.33 
(0.94) 
8.9 
(1.2) 
(73.8) 
55.8 
(10.7) 
257/483 
(53%) 
Caucasian 
(63.1%) 
NR 123/483 
(26.2%) 
s12 
Heinrich 2010a 
NETHERLANDS  
 
584 
(demographics 
for 537 
completing 
baseline 
Primary care 
(I/RCT) 
T2 N N N N 16.9 
(13.6) 
6.5 
(.80) 
(47.5) 
59 
(5.3) 
269/584 
(46%) 
NR NR 37/533 
(7.0%) 
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questionnaire/ 
570 providing 
clinical data) 
s13 
Hermanns 2009a 
GERMANY 
50 Diabetes 
clinic 
(I/RCT) 
T1 N N N N 30.7 
(18.8) 
8.1 
(1.5) 
(65.0) 
41.7 
(12.3) 
26/50 
(52%) 
NR All 14/49 
(28.0%) 
s14 
Hermanns 2012 
GERMANY  
186 
(demographics 
for 167 
included in per 
protocol 
analysis) 
Diabetes 
clinic 
(I/RCT) 
T2 N N N N 50.0 
(9.7) 
8.3 
(1.3) 
(67.2) 
63.5 
(7.9) 
92/167 
(55%) 
NR All 31/167 
(18.6%)  
s15 
Hopkins 2012b 
UK  
639 (with at 
least some pre 
AND post 
data) 
Diabetes 
clinic (I/non-
RCT)  
T1 N N N N 25.2 
(17.4)  
8.7 
(1.6) 
(71.6) 
38.8 
(12.8)  
NR NR All 103/484 
(21.2%)   
s16 
Keen 2012 
UK 
124 
(completing 
DAFNE 
course with 
pre AND post 
data) 
Diabetes 
clinic (I/non-
RCT)  
T1 N N Y N NR 8.6 
(1.4) 
(70.5) 
42.5 
(11.1) 
51/124 
(41%) 
NR All 21/124 
(16.9%)  
s17 
Keers 2005a  
NETHERLANDS 
69 (with at 
least some pre 
AND post 
data)  
Diabetes 
clinic (I/non-
RCT)  
T1/2 Y N Y N 38.0 
(22.0) 
8.5 
(1.3) 
(69.4) 
44.0 
(13.0)  
34/69 
(49.3%) 
NR NR 27/56 
(48.0%) 
s18 
Sturt 2008b 
UK 
245 Primary care 
(I/RCT) 
T2 N N Y N 18.7 
(15.6) 
8.8 
(1.5) 
(72.7) 
62.0 
(NR) 
148/245 
(60%) 
Caucasian 
(79.2%) 
NR 26/216 
(12.0%) 
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Khunti 2012b 
UK 
 
824 
(demographics 
for 604 
providing 
clinical data & 
536 
completing 
questionnaires
) 
Primary care 
(I/RCT) 
T2 N N N N NR 8.0 
(2.1) 
(63.9) 
60.1 
(11.8) 
271/604 
(55%) 
Caucasian 
(97.1%) 
17/604 
(28%) 
35/461 
(7.6%)  
s20  
van Bastelaar 2010 
NETHERLANDS 
1012 
(demographics 
for 627 with 
complete data) 
Diabetes 
clinic 
(I/RCT) 
T1/2 N Y N N 20.0 
(18.0)  
7.8 
(1.3) 
(61.7) 
 53.0 
(15.0)  
313/627 
(50%) 
NR (‘Native 
Dutch’ 
(90%)  
571/627 
(91%) 
93/627 
(15.0%) 
s21 
van Bastelaar 2012  
NETHERLANDS 
& BELGIUM 
255 Community 
(I/RCT) 
T1/2 N Y N N 40.0 
(19.0) 
7.4 
(1.3) 
(57.4) 
50.0 
(12.0) 
100/255 
(39%) 
Caucasian 
(89%) 
183/255 
(72%) 
127/255 
(49.8%)  
s22 
Fisher 2013  
USA 
392 (with pre 
AND post 
data) 
Diabetes 
clinic & 
community 
(I/RCT) 
T2 Y  N  N N 2.4 
(0.9) 
7.4 
(1.61) 
(57.4) 
56.1 
(9.6) 
181/392 
(46%) 
Caucasian 
(40.1%)  
70/392 
(18%) 
95/392 
(24.2%) 
s23 
Malanda 2015a 
NETHERLANDS  
181 Diabetes 
clinic 
(I/RCT) 
T2 N N Y  N 10.2 
(7.2) 
7.6 
(0.8) 
(59.6) 
61.5 
(7.8)  
120/181 
(66%) 
NR None 7/173 
(4.0%) 
s24 
Pibernik-
Okanovic 2015a 
CROATIA 
209 Diabetes 
clinic 
(I/RCT)  
T2 N Y  N N 39.8 
(19.9) 
7.3 
(1.1) 
(56.3) 
58.1 
(5.8) 
96/209 
(46%) 
NR 93/209 
(44%) 
101/208 
(48.5%) 
 s25 
Elliott 2012b  
UK 
479 Diabetes 
clinic (I/non-
RCT) 
T1 N N N N 29.1 
(20.2) 
8.7 
(1.5) 
(71.6) 
41.2 
(13.9) 
230/479 
(48%) 
NR All 112/357 
(31.0%) 
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s26 
Archer 2012  
UK 
99 Diabetes 
clinic (I/non-
RCT) 
T1/2 NR NR NR NR 37.4 
(18.6) 
NR 44.3 
(13.2) 
63/96 
(64%) 
NR 73/99 
(74%) 
46/99 
(46.5%) 
s27 
Hermanns 2015a 
GERMANY 
214 Diabetes 
clinic 
(I/RCT) 
T1/2 N Y N N 38.6 
(18.3) 
8.9 
(1.8) 
(73.8) 
43.3 
(14.3) 
93/214 
(44%) 
NR NR 104/208 
(50.0%) 
s28 
Lindsay 2011a 
UK 
136 Diabetes 
registry 
(I/non-RCT)  
T2 N N N N 13.0 
(NR) 
NR 65.4 
(12.0)  
81/136 
(59%)  
NR (Asian 
6%)  
NR 18/131 
(13.7%) 
s29 
Van Dijk de Vries 
2015a 
NETHERLANDS 
264 Diabetes 
clinic 
(I/RCT) 
T2 N N N N 29.3 
(18.3) 
6.9 
(NR) 
(52.3) 
64.6 
(9.5) 
142/264 
(54%) 
NR (Non-
Western 
.8%) 
60/264 
(23%) 
64/257 
(24.9%)  
s30 
Stoop 2014 
NETHERLANDS 
774 Primary care 
(I/RCT) 
T2 N N N N 3.0 
(NR) 
6.6 
(NR) 
(48.6) 
68.0 
(NR) 
439/774 
(57%) 
NR (Ethnic 
Minority 
Groups 1%) 
123/757 
(16%) 
29/774 
(3.7%) 
s31 
Karlsen 2012 
NORWAY 
425 
(demographics 
for 378 
completing 
questionnaire 
adequately) 
Primary care 
& 
community 
(CS) 
T2 N N N N 26.0 
(18.0) 
7.1 
(1.1) 
(54.1) 
58.1 
(8.7) 
205/378 
(54%) 
NR 108/378 
(29%)  
84/378 
(22.2%)  
s32 
Miller 2008 
USA 
160 
(demographics 
for 131 that 
‘completed the 
study’) 
Community 
(CS) 
T2 N N N N 34.6 
(23) 
9.0 
(2.4) 
(74.9) 
39.4 
(8.2) 
All 
female 
All African 
American  
47/131 
(37%) 
52/131 
(40.0%) 
s33 
Fisher 2008  
USA 
506 Diabetes 
clinic (L) 
T2 N N N N NR NR 57.8 
(9.9) 
218/506 
(43%) 
Caucasian 
(36.7%) 
76/506 
(15%) 
 91/506 
(18.0%)  
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s34 
Lehmann 2011 
TURKEY 
154 (most 
demographics 
for 151 
included on 
analysis) 
Diabetes 
clinic (CS) 
T2 N N N N 26.8 
(18.7) 
6.7 
(1.0) 
(49.7) 
56.0 
(10.0) 
69/151 
(46%) 
NR None  40/151 
(26.5%) 
s35 
Fleer 2013a 
NETHERLANDS 
347 Diabetes 
clinic (L) 
T1/2 N N N N NR 7.8 
(1.4) 
(61.7) 
50.4 
(13.2) 
181/347 
(52.2%) 
NR 313/347 
(91%) 
34/346 
(9.8%) 
s36 
Fritschi 2012 
USA 
83 Diabetes 
clinic (CS) 
T2 N N N N 2.5 
(1.0) 
7.4 
(1.9) 
(57.4) 
53.0 
(6.5) 
All 
female 
Black 
(42.2%)  
12/83 
(14%) 
27/83 
(32.5%) 
s37 
Kokoszka 2009 
POLAND 
101 Diabetes 
clinic (CS) 
T2 N N N N 27.5 
(18.4) 
8.1 
(1.8) 
(65.0) 
63.2 
(10.7) 
51/101 
(50%) 
NR 67/101 
(66%) 
25/101 
(24.8%) 
s38 
Nichols 2000b 
USA 
1178 Diabetes 
registry (CS) 
T2 N N N N NR 7.9 
(1.4) 
(62.8) 
65.6 
(NR) 
NR NR All 477/1033 
(46.2%)  
s39 
Hermanns 2006 
GERMANY 
376 Diabetes 
clinic (CS) 
T1/2 N N N N 30.6 
(18.1)  
8.5 
(1.6) 
(69.4) 
52.2 
(14.3) 
228/376 
(61%) 
NR 286/376 
(76%) 
116/376 
(30.9%)  
s40 
Hermanns 2010 
GERMANY 
130 Diabetes 
clinic (L) 
T2 N N Y N 30.0 
(16.7) 
8.7 
(1.6) 
(71.6) 
55.8 
(8.8) 
85/130 
(65%) 
NR 57/130 
(44%) 
39/130 
(30.0%) 
s41 
Nozaki 2009 
JAPAN 
304 Diabetes 
clinic (L) 
T2 N N N N 33.0 
(21.0) 
7.3 
(1.2) 
(56.3) 
61.9 
(11.0) 
170/304 
(56%) 
NR NR 107/304 
(35.2%) 
s42 
Wagner 2010a 
USA 
153 Primary care 
& 
community 
(L) 
T2 N Y N N 51.0 
(24.1) 
6.7 
(1.2) 
(49.7) 
60.1 
(9.7) 
All 
female 
NR 26/153 
(17%) 
75/140 
(53.6%)  
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s43 
Duda-Sobczak 
2012b  
POLAND 
213 NR (CS) T1 NR NR NR NR NR 8.2 
(1.4) 
(66.1) 
26.6 
(6.0) 
97/213 
(46%) 
NR All  43/165 
(26.1%) 
s44 
Ikeda 2014a 
JAPAN 
152 
(demographics 
reported for 
149 included 
in analysis) 
Diabetes 
clinic (CS) 
T2 N N N N 29.8 
(18.7) 
7.6 
(1.2) 
(59.6) 
60.6 
(8.6) 
91/149 
(61%) 
All Japanese  46/149 
(31%) 
52/152 
(34.2%) 
s45 
Ikeda 2014a 
USA 
64 
(demographics 
reported for 50 
included in 
analysis) 
NR (CS) T2 N N N N 24.9 
(23.1) 
7.6 
(1.6) 
(59.6) 
60.0 
(10.1) 
25/50 
(50%) 
NR (All 
Euro-
Americans) 
23/50 
(46%) 
 14/51 
(27.5%) 
s46 
Joensen 2013b 
DENMARK 
2419 Diabetes 
clinic (CS) 
T1 N N N N 1.9 
(NR) 
8.1 
(NR) 
(65) 
51.6 
(NR) 
1258/ 
2419 
(52%) 
NR All 225/2295 
(9.8%) 
s47 
Sheils 2012  
UK 
124 
(demographics 
for 108 with 
complete 
PAID data) 
Diabetes 
clinic (CS) 
T1 N N N N 20.7 
(17.5) 
8.8 
(1.5) 
(72.7) 
44 
(12.9) 
49/108 
(45%) 
NR All 18/108 
(16.6%) 
s48 
Crosby-Nwaobi 
2013a 
UK 
380 Primary care 
(CS) 
T2 N N N Y NR  8.3 
(1.9) 
(67.2) 
64.8 
(10.8) 
214/380 
(56%) 
Black 
(50.4%) 
193/380 
(51%) 
10/374 
(2.7%) 
s49 
Baek 2014  
USA 
119 Diabetes 
clinic, 
primary care 
& previous 
T2 N N N N 2.3 
(1.2) 
7.9 
(1.9) 
(62.8) 
56.3 
(9.7) 
43/119 
(36%) 
Black or 
African 
American 
(61.4%) 
49/119 
(41%) 
33/119 
(27.7%) 
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research 
study (CS) 
s50 
Aikens 2012b 
USA 
287 
(demographics 
for 253 
providing 
baseline data) 
Diabetes 
registry (L) 
T2 N N N N 22.1 
(19.0) 
7.6 
(1.6) 
(59.6) 
57.3 
(8.3) 
127/253 
(50%) 
African 
American 
(55%) 
101/253 
(40%) 
53/253 
(21.0%) 
s51 
Keers 2004 
NETHERLANDS 
315 Diabetes 
clinic & 
patients 
attending 
education 
programme 
(CS) 
T1/2 NR NR NR N 30.0 
(19.8) 
8.1 
(1.2) 
(65.0) 
46.4 
(13.1) 
147/315 
(46.7%) 
NR NR 98/315 
(31.1%)  
s52 
Bot 2010b 
NETHERLANDS 
114 Diabetes 
clinic (L) 
T1/2 N Y N N 29.4 
(10.9) 
7.5 
(1.1) 
(58.5)  
65.3 
(8.2) 
62/114 
(54%) 
NR NR 22/75 
(29.3%)  
s53 
Pouwer 2006b 
NETHERLANDS 
112 Diabetes 
clinic/ 
previous 
research 
study (CS) 
T1/2 N N N N 44.0 
(22.0) 
7.8 
(1.2) 
(61.7) 
52.0 
(18.0) 
61/112 
(54%) 
NR 104/112 
(93%)  
22/89 
(24.7%)  
s54 
Sigurdardottir 
2008a  
ICELAND 
92 
(demographics 
for 90 
completing 
questionnaires
) 
Diabetes 
clinic (CS) 
T1/2  N N N N 27.9 
(18.1)  
7.7 
(1.41) 
(60.7) 
38.1 
(11.1) 
48/90 
(53%) 
NR All 19/85 
(22.4%) 
s55 
Aikens 2014a 
USA 
303 Diabetes 
clinic (L) 
T2 N N N N 16.4 
(16.4) 
NR 66.6 
(9.8) 
294/303 
(97%) 
Caucasian 
(92.9%)  
NR 24/300 
(8.0%) 
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Lange 2013 
GERMANY 
306 Diabetes 
clinic (CS) 
T1   N N N N 26.8 
(20.0) 
8.3 
(1.6) 
(67.2) 
24.1 
(3.5) 
162/306 
(53%) 
NR All 77/306 
(25.0%) 
s57 
Hearnshaw 2007b 
UK 
180 
(demographics 
for 176 
completing 
questionnaires
)  
Primary care 
(CS) 
T2 N N N N NR NR 62.2 
(10.4) 
89/176 
(51%) 
Caucasian 
(91%) 
NR 24/136 
(17.6%)  
s58 
Grant 2005b 
USA 
909 (Type 2 
sample) - 
demographics 
for 896 
classifiable re: 
internet use)  
Primary care 
(CS) 
T2 N N N N NR 7.4 
(1.4) 
(57.4) 
66.2 
(12.4) 
461/896 
(51.5%) 
Caucasian 
(82.7%) 
NR 126/815 
(15.5%)  
 
NR: not reported; NA: not applicable; N: no; Y: yes 
I/RCT: randomised controlled trial; I/non-RCT: intervention study but not a randomised controlled trial; L: longitudinal observation study; CS: cross-sectional study 
aDifference between the number of participants for which elevated DD rate data was provided and those included in the study/for whom demographic data were reported; 
bSubstantial difference between the number of participants for which elevated DD rate data was provided and those included in the study/for whom demographic data were 
reported. 
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Figure 2 Forest plot illustrating the rate of elevated diabetes distress across all study 
populations 
  
 16 
 
Table 3 Participant characteristics as predictors of the rate of elevated diabetes distress 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*P<0.05; **P<0.01; ***P<0.001 
 
 
 R² (%) ß SEß 95% CIs P value 
Model 1 <0.01     
     Age  -0.03   0.01   -0.05 to -0.01 0.003**   
Model 2 12.48     
     Gender  -2.05 0.59   -3.21 to -0.89 <0.001*** 
Model 3 <0.1     
     HbA1c   0.19 0.16    -0.13 to 0.52    0.24   
Model 4 <0.01     
     Health care context  -0.51  0.23 -0.96  -0.07  0.02*     
Model 5 9.79     
     Age  -0.01 0.02 -0.04 to 0.02 0.56 
     Gender  -2.57 0.82 -4.17 to -0.97 0.002** 
     HbA1c   0.07 0.19 -0.31 to 0.45 0.72 
     Health care context  -0.66 0.27 -1.18 to -0.14 0.01* 
